DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
AUY922 is an investigational drug.
There have been 25 clinical trials for AUY922. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2012.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Novartis Pharmaceuticals, Novartis, and National Cancer Institute (NCI).
There are thirty-nine US patents protecting this investigational drug and four hundred and fifteen international patents.
Recent Clinical Trials for AUY922
|A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer||Novartis Pharmaceuticals||Phase 2|
|Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer||National Cancer Institute (NCI)||Phase 1|
|Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer||Jonsson Comprehensive Cancer Center||Phase 1|
Top disease conditions for AUY922
Top clinical trial sponsors for AUY922
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AUY922||Start Trial||Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta||Berg LLC (Nashville, TN)||Start Trial|
|AUY922||Start Trial||Resorcinol derivative as HSP90 inhibitor||CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (Lianyungang, CN)||Start Trial|
|AUY922||Start Trial||Compounds targeting proteins, compositions, methods, and uses thereof||Biotheryx, Inc. (Chappaqua, NY)||Start Trial|
|AUY922||Start Trial||Chimeric compounds targeting proteins, compositions, methods, and uses thereof||BioTheryX, Inc. (Chappaqua, NY)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|AUY922||European Patent Office||3152307||2034-06-06||Start Trial|
|AUY922||World Intellectual Property Organization (WIPO)||2015188198||2034-06-06||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|